Clinical trials: Drug-Drug Interaction (DDI), open to volunteers
Steatohepatitis, Nonalcoholic, Osteo Arthritis
DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine
This is a Phase 1, open-label, 2-part, fixed-sequence, single-center, two-period, drug-drug interaction trial in healthy adult participants to determine if ECC0509 administration at steady state affects the pharmacokinetics (PK)…
- Trial name
- NCT07873229
- Testing
- ECC0509, Metformin, Caffeine
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eccogene
Ulcerative Colitis, Crohn's Disease
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
This is an open-label, single group, 2-period, Phase 1, single-arm study. The primary purpose of this study is to investigate the effects of duvakitug on the pharmacokinetics of selected cytochrome P450 substrates in adult…
- Trial name
- NCT07923383
- Testing
- Duvakitug
- Volunteers
- 25 people
- Sponsor
- Sanofi
Drug Drug Interaction (DDI)
Study on the Drug Interaction Between Buagafuran and Voriconazole
This study is a non-randomized, open label trial aimed at evaluating the drug interaction between Buagafuran capsules and voriconazole tablets in Chinese adult healthy participants.The research period is 7 days in total.
- Trial name
- NCT07457203
- Testing
- Buagafuran, Voriconazole
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Beijing Union Pharmaceutical Factory Ltd
Drug Drug Interaction (DDI), Pharmacokinetics and Pharmacodynamics
Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity
This is a Phase I, open-label, two-cohort study designed to evaluate the drug-drug interaction potential of multiple-dose UBT251 Injection in adult participants with overweight or obesity.
- Trial name
- NCT07785934
- Testing
- UBT251, Metformin hydrochloride, Warfarin Sodium
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Healthy Adult Participants
A Phase 1 Multiple Dose Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, Drug-Drug Interactions, and Pharmacokinetics of TBD11
This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose trial of TBD11 in healthy adults. It includes a dedicated open-label cohort in which TBD11 will be administered as a single dose with either a strong…
- Trial name
- NCT07883226
- Testing
- TBD11 (300 mg), Itraconazole (200 mg), Rifampicin 600mg
- Where
- South Africa
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute
Healthy Participants
A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants
The purpose of this study is to assess the effect of multiple doses of phenytoin, a strong cytochrome P450 (CYP)3A4 inducer, and itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetic (PK) profile of DAK539 (hereafter…
- Trial name
- NCT07783503
- Testing
- Pelabresib, Phenytoin, Itraconazole
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteers
Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants
The purpose of this study is to evaluate the safety and pharmacokinetics of BMS-986533 in healthy participants receiving single and multiple doses, to assess food and pH effects on the relative bioavailability of BMS-986533, and…
- Trial name
- NCT07629999
- Testing
- BMS-986533, Famotidine, Dabigatran Etexilate
- Where
- United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HCV Infection
Drug-Drug Intercations and Direct Acting Antiviral Agents Against HCV
Background: Currently used direct-acting antivirals (DAA) share pharmacokinetic pathways with many comedications commonly used in patients with chronic hepatitis C virus (HCV) infection, therefore drug-drug interactions (DDI)…
- Trial name
- NCT06928259
- Where
- 4 sites in Spain
- Volunteers
- 728 people
- Sponsor
- University of Seville
Drug Drug Interaction (DDI)
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
- Trial name
- NCT07265466
- Testing
- JP-1366 and clopidogrel, JP-1366 and aspirin, JP-1366 and atorvastatin
- Where
- South Korea
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Onconic Therapeutics Inc.
Healthy Male Volunteers
A Study in Healthy Male Participants to Compare How CHF10196 Affects How the Body Absorbs and Processes Two Commonly Used Medicines: Dabigatran, a Blood Thinner, and Rosuvastatin, a Medicine Used to Lower Cholesterol
The purpose of this study is to assess the potential drug-drug interaction of CHF10196 (a dipeptidyl peptidase 1 inhibitor) and its metabolite on the pharmacokinetics of dabigatran (a P-glycoprotein substrate) and Rosuvastatin (a…
- Trial name
- NCT07744386
- Testing
- Dabigatran Etexilate, Rosuvastatin, CHF10196
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Healthy Volunteers, Drug-Drug Interaction (DDI)
A Drug-Drug Interaction Study Between NTQ5082 Capsules and Midazolam Oral Solutio
This is a single-center, non-randomized, open-label, single-sequence, self-controlled drug-drug interaction study in healthy participants.
- Trial name
- NCT07745439
- Testing
- NTQ5082, Midazolam
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- The Third Xiangya Hospital of Central South University
Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib…
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
- Trial name
- STELLAR-002 (NCT05176483)
- Testing
- Zanzalintinib, Nivolumab, Ipilimumab
- Where
- 122 sites in United States, Australia and 11 more
- Volunteers
- 1,394 people
- Sponsor
- Exelixis
Gastrointestinal Neoplasms, Genitourinary Cancer
Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study
Immune checkpoint inhibitors (ICIs) (also called "immunotherapy") are an effective family of anti-cancer drugs, but they can cause serious side effects.
- Conditions
- Gastrointestinal Neoplasms, Genitourinary Cancer, Thoracic Cancer, Sarcoma
- Trial name
- NCT07389525
- Testing
- ICI Therapy
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Indiana University
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Drug-Drug Interactions of JMKX003142 in Healthy Participants
This is a single-center, non-randomized, open-label, self-controlled, Phase I clinical trial to evaluate the drug-drug interactions (DDI) of JMKX003142 tablets in healthy adult participants.
- Trial name
- NCT07565441
- Testing
- JMKX003142 tablets, Fluconazole Capsules, Cocktail Substrates (Midazolam Oral Solution, Rosuvastatin Calcium Tablets, and Digoxin Tablets)
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Jemincare
Healthy Volunteer, Pharmacokinetics
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
This is a Phase 1, open-label, three-part, study in approximately 96 healthy adult participants between 18 and 55 years of age (both inclusive) (16 participants in Part 1, 20 participants in Part 2 and , and approximately 60…
- Conditions
- Healthy Volunteer, Pharmacokinetics, Safety, Drug-Drug Interaction (DDI)
- Trial name
- NCT06733675
- Testing
- Ledaborbactam etzadroxil, Ceftibuten, Ceftibuten-ledaborbactam etzadroxil
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
PK Drug-drug Interaction Study
LTG-321 - Itraconazole Drug-drug Interaction (DDI) Study
This Phase 1, single-center, open-label, randomized, parallel-group study will evaluate the effect of itraconazole on the PK of LTG-321 and its metabolite(s), and the safety and tolerability of LTG-321 administered alone and in…
- Trial name
- NCT07915947
- Testing
- LTG-321, Itraconazole (200 mg)
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Latigo Biotherapeutics
Healthy Volunteers
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
The purpose of this study is to assess the drug-drug interaction (DDI) of repinatrabit with ethinyl estradiol/norethindrone or norethisterone (EE/NE), metformin, rosuvastatin, carbamazepine, and methotrexate in healthy…
- Trial name
- NCT07446400
- Testing
- Repinatrabit, EE/NE, Metformin
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer
Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors
An open-label drug-drug interaction study to evaluate the effects of pralsetinib (Gavreto) on the pharmacokinetics of a CYP450 probe substrate cocktail and, in female participants, a hormonal probe substrate, in participants with…
- Conditions
- NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer, Solid Tumor Malignancies, Advanced Malignancies
- Trial name
- NCT07704658
- Testing
- Pralsetinib, CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive
- Where
- 2 sites in Spain
- Volunteers
- 12 people
- Sponsor
- Rigel Pharmaceuticals
Healthy Volunteers (HV)
Drug-Drug Interaction Study of MDR-001 With Rifampin and Itraconazole in Healthy Adult Participants
A Phase I, open-label, fixed-sequence, two-part drug-drug interaction study in healthy Chinese adults to evaluate the effect of multiple-dose rifampin (Part A) or itraconazole (Part B) on the single-dose pharmacokinetics of…
- Trial name
- NCT07550621
- Testing
- MDR-001, Rifampin, Itraconazole
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- MindRank AI Ltd
Advanced Malignancies
A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
This drug-drug interaction (DDI) study aims to evaluate the impact of pelabresib at steady-state plasma concentrations on the pharmacokinetic (PK) profile of A) a single dose of repaglinide and a single dose of midazolam, and B)…
- Trial name
- NCT07340190
- Testing
- pelabresib, repaglinide, midazolam
- Where
- 6 sites in France, Italy and 1 more
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals